Risk of Termination of Partnerships for Product In-Licensing, Joint Sales, Joint Development and Other Activities
First written in FY2016. 15 of 24 entries say "Restated". Latest entry: FY2024-Q2.
The whole theme swung hardest in 2020: 9 of 43 companies on the "Worse" side.
8 other companies' latest entry also says "Materialised".
- FY2024-Q2MaterialisedAnnual report
「The contracts terminated during the second quarter under review were as follows: Technology out-licensing for the anti-ulcer drug Promac in South Korea and export of the product Purchase agreement for the active pharmaceutical ingredient of the anti-ulcer drug Promac」
The technology out-licensing agreement for Promac in South Korea with SK Chemicals Co., Ltd. and the purchase agreement for Promac's active pharmaceutical ingredient with Hamari Chemicals, Ltd. ended. - FY2023MitigatedAnnual report
「The Group is working to minimize the impact on its performance of any termination of partnerships or other events by developing multiple core products that serve as earnings pillars.」
As a response to the risk of partnership termination, the Company has explicitly stated its policy of developing multiple core products that serve as earnings pillars. - FY2023-Q3RestatedAnnual report
「There were no material business contracts for which a decision to conclude the contract was newly made or which were newly concluded during the third quarter under review.」
It has been explained that there were no new material contracts concerning partnerships involving product in-licensing, co-promotion, co-development and other arrangements. - FY2023-Q2RestatedAnnual report
「There were no material business contracts for which a decision to conclude the contract was newly made or which were newly concluded during the second quarter under review.」
It has been explained that there were no new material contracts or material changes concerning partnerships involving product in-licensing, co-promotion, co-development and other arrangements. - FY2023-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of termination of partnerships involving product in-licensing, co-promotion, co-development and other arrangements. - FY2022-Q3RestatedAnnual report
「There were no material business contracts for which a decision to conclude the contract was newly made or which were newly concluded during the third quarter under review.」
It has been explained that there were no new material contracts during the third quarter under review and no material changes in partnerships involving product in-licensing, co-promotion, co-development and other arrangements. - FY2022-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of termination of partnerships involving product in-licensing, co-promotion, co-development and other arrangements. - FY2022-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of termination of partnerships involving product in-licensing, co-promotion, co-development and other arrangements. No new material contracts were concluded during the quarter. - FY2021-Q2MaterialisedAnnual report
「The contracts terminated during the second quarter under review were as follows: Technology in-licensing and other agreements; contracting company: Tillotts Pharma AG (consolidated subsidiary); counterparty: Prof John Rhodes and Dr Brian Evans; United Kingdom; agreement concerning royalty payments associated with the development and sale of Asacol.」
The termination of the agreement between Tillotts Pharma AG and Prof John Rhodes and Dr Brian Evans concerning royalty payments associated with the development and sale of Asacol is disclosed. - FY2020MaterialisedAnnual report
「In particular, in Japan, following the termination of the sales partnership for Asacol with Kyowa Kirin Co.,Ltd. at the end of March 2020 and the transition to independent sales by the Company from April 2020, the Company will further strengthen its information-provision activities for medical institutions.」
The sales partnership for Asacol with Kyowa Kirin Co.,Ltd. ended, and the Company transitioned to independent sales. As a response following the termination of the partnership, the Company has stated that it will strengthen its information-provision activities for medical institutions. - FY2020-Q3MaterialisedAnnual report
「The contracts terminated during the third quarter under review were as follows:」
During the third quarter under review, the basic agreement concerning transactions in products with Kotobuki Pharmaceutical Co., Ltd. and the tripartite agreement concerning Marslen products ended. In addition, new development and sales agreements concerning Acophide, ASACOL and other products were concluded. - FY2020-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of termination of partnerships involving product in-licensing, co-promotion, co-development and other arrangements. - FY2019RestatedAnnual report
「These relationships may be terminated for various reasons that arise in the future. If termination actually occurs, it may no longer be possible to achieve the expected business results, which could affect the performance and financial position of the Group.」
The risk of termination of partnerships involving product in-licensing, co-promotion, co-development and other arrangements continues to be disclosed. - FY2019-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of termination of partnerships involving product in-licensing, co-promotion, co-development and other arrangements. - FY2019-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of termination of partnerships involving product in-licensing, co-promotion, co-development and other arrangements. - FY2019-Q1MaterialisedAnnual report
「The contracts terminated during the first quarter under review were as follows: DAIICHI SANKYO COMPANY,LIMITED; Japan; an amended agreement and contract concerning the grant of a sublicense for the exclusive domestic sales rights, and sales and other matters, for Hamp Injection 1000, a treatment for acute heart failure.」
It states that the contract with DAIICHI SANKYO concerning the exclusive domestic sales rights and other rights for Hamp Injection 1000 ended, with the termination of the partnership and sales contract newly appearing as an actual event. - FY2018-Q3MaterialisedAnnual report
「The contract for TP09, a treatment for familial adenomatous polyposis being developed in a Phase III trial jointly with US-based Cancer Prevention Pharmaceuticals, INC., has ended.」
The joint development agreement concerning TP09 with Cancer Prevention Pharmaceuticals,INC. ended, and the termination of the partnership actually occurred. - FY2018-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of termination of partnerships involving product in-licensing, co-promotion, co-development and other arrangements. - FY2018-Q1MaterialisedAnnual report
「Following the termination of the license agreement with EA Pharma Co., Ltd. concerning the novel proton pump inhibitor Z-215, all ongoing research and development was discontinued, and the related liquidation costs were recognized as research and development expenses in the first quarter under review.」
The license agreement with EA Pharma concerning Z-215 ended, resulting in the discontinuation of research and development and liquidation costs associated with the termination of the partnership. - FY2017RestatedAnnual report
「These relationships may be terminated for various reasons that arise in the future. If termination actually occurs, it will no longer be possible to achieve the expected business results, and」
The risk of termination of partnerships involving product in-licensing, co-promotion, co-development and other arrangements continues to be disclosed. - FY2017-Q3RestatedAnnual report
「During the nine months ended the third quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of termination of partnerships involving product in-licensing, co-promotion, co-development and other arrangements. - FY2017-Q2RestatedAnnual report
「During the six months ended the second quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of termination of partnerships involving product in-licensing, co-promotion, co-development and other arrangements. - FY2017-Q1RestatedAnnual report
「During the three months ended the first quarter of the current fiscal year, there were no new occurrences or material changes in the principal risks likely to affect the business results or financial condition of the Group.」
It has been explained that there have been no new occurrences or material changes in the risk of partnership termination. - FY2016First statedAnnual report
「These relationships may be terminated for various reasons that arise in the future. If termination actually occurs, it will no longer be possible to achieve the expected business results, and」
This is described as a risk associated with operating a business based on multiple partnerships.